Is It Too Late to Buy Eli Lilly?

Eli Lilly’s weight-loss portfolio generated more than $12B in sales in the latest quarter, supporting a total sales gain of 56% and reinforcing its GLP-1 market leadership (about 60% of the U.S. market and 53% internationally). The article highlights ongoing growth drivers including tirzepatide (Mounjaro/Zepbound), the newly launched oral weight-loss drug Foundayo, and a promising phase 3 pipeline candidate retatrutide. While competition is expected from peers pursuing oral/injectable weight-loss drugs, the piece argues demand remains high and Lilly’s valuation looks “reasonably priced,” suggesting a positive near-to-medium term outlook for LLY.

Analysis

The market is no longer debating whether obesity drugs are real; it is debating how much economics survive once the category gets crowded. For LLY, the next leg is less about another awareness-driven rerate and more about manufacturing scale, formulary access, and persistence of therapy, which favors the incumbent with the deepest supply chain. That supports continued compounding, but the upside path is more likely gradual than explosive.

Relative pressure sits on NVO first. In a duopoly, every incremental share loss matters because it feeds directly into price negotiations and pharmacy benefit manager leverage, so the real risk over the next 1-3 quarters is not volume collapse but net price erosion disguised as growth. VKTX remains a credible optionality trade, but it is a financing and execution story, not yet a structural threat; any future entrant forces the incumbents to spend more on access, not less.

Contrarian risk: consensus is treating the market as large enough for multiple winners, but payer behavior can create an artificial ceiling well before the addressable patient pool is saturated. The oral format may broaden adoption, yet it can also cannibalize higher-economics injectables and dilute margins if mix shifts faster than expected. The cleanest falsifier for the bullish LLY case is decelerating net new patient growth or gross margin compression in the next earnings cycle, which would challenge the 'safe growth' premium quickly.

Key Decisions for Investors

• Long LLY / short NVO as a 3-6 month relative-value trade; thesis is continued share consolidation plus better pipeline optionality for LLY. Risk: NVO oral uptake or pricing actions stabilize share, narrowing the spread.
• Do not chase LLY outright after strength; prefer entry on a post-earnings pullback or via cash-secured put selling if implied vol remains elevated. The stock can still work, but valuation is now the primary risk, not product novelty.
• Keep VKTX on a watchlist only, or express it with a small call-spread rather than common stock, into the next phase 3 catalyst. This is a binary event trade; upside is large if data are clean, but downside from one mixed readout is severe.
• Set a hard alert on LLY quarterly gross-to-net and prescription persistence. If margin compresses or patient growth slows materially, cut the long thesis quickly; that would signal the market is extrapolating too far ahead of reimbursement reality.